Founded in 2012 and headquartered in Shanghai, China, Biointron is a high-throughput recombinant antibody/protein expression provider. With a commitment to quality, the company offers a range of services, from gene sequence to purified antibodies, in just two weeks. Biointron has successfully delivered tens of thousands of recombinant antibodies/proteins to nearly 1,000 biotech/biopharma companies worldwide. Their antibody discovery platforms include single B screening, phage display, and antibody humanization & affinity maturation. Additionally, they offer a comprehensive catalog of research-grade biosimilar antibodies and isotype control antibodies, all subject to strict experimental verification and quality control. With their licensed CHO-K1 cell line, Biointron guarantees high-yield (>5 g/L for antibody) and speedy timeline stable cell line service.